Jasper Therapeutics (NASDAQ:JSPRW – Get Free Report) will likely be posting its results before the market opens on Friday, August 7th. Analysts expect the company to announce earnings of ($0.2471) per share for the quarter.
Jasper Therapeutics Stock Up 10.1%
Shares of NASDAQ JSPRW opened at $0.01 on Thursday. Jasper Therapeutics has a 1 year low of $0.01 and a 1 year high of $0.15. The firm’s 50-day moving average is $0.01 and its 200-day moving average is $0.02.
Jasper Therapeutics Company Profile
Jasper Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.
The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.
Read More
- Five stocks we like better than Jasper Therapeutics
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
